TGFB2 and hepatocellular carcinoma: For these tumor types, donors with selective copy number gains of IL10 or TGFB2 were found to have a worse overall survival than that of donors without these copy number gains (p = 0.0551 for IL10 in Liver-HCC; p = 0.1 for TGFB2 in Lung-AdenoCA; p = 0.0202 for both IL10 and TGFB2 in Cervix-SCC; Fig. 3b).